Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
33.14 USD | +1.42% | -11.96% | +54.65% |
05-15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
05-13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.65% | 1.32B | |
+12.02% | 116B | |
+12.98% | 106B | |
-9.23% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-14.55% | 16.33B | |
+6.55% | 14.14B | |
+30.68% | 12.02B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Transcript : Aeglea BioTherapeutics, Inc. - Special Call